RE: results End of Q1 202223 Mar 2022 12:50
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic ("PK") study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients.
Key highlights
· Medical and Health Products Regulatory Agency ("MHRA") approves commencement of the PK study
· Volunteers have been selected and approved for inclusion in the PK study
· Volunteer dosing to commence on 15 February 2022
· Study on track to deliver results around the end Q1 2022